AU2021342783A1 - Compounds and compositions as sppl2a inhibitors - Google Patents

Compounds and compositions as sppl2a inhibitors Download PDF

Info

Publication number
AU2021342783A1
AU2021342783A1 AU2021342783A AU2021342783A AU2021342783A1 AU 2021342783 A1 AU2021342783 A1 AU 2021342783A1 AU 2021342783 A AU2021342783 A AU 2021342783A AU 2021342783 A AU2021342783 A AU 2021342783A AU 2021342783 A1 AU2021342783 A1 AU 2021342783A1
Authority
AU
Australia
Prior art keywords
methyl
benzo
oxo
pyrazolo
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021342783A
Other languages
English (en)
Other versions
AU2021342783A9 (en
Inventor
Trixi Brandl
Claus Ehrhardt
Robert Epple
Christian Markert
Pascal Rigollier
Juraj Velcicky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2021342783A1 publication Critical patent/AU2021342783A1/en
Publication of AU2021342783A9 publication Critical patent/AU2021342783A9/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021342783A 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors Pending AU2021342783A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079604P 2020-09-17 2020-09-17
US63/079,604 2020-09-17
PCT/IB2021/058398 WO2022058902A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors

Publications (2)

Publication Number Publication Date
AU2021342783A1 true AU2021342783A1 (en) 2023-05-18
AU2021342783A9 AU2021342783A9 (en) 2024-09-12

Family

ID=77897680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021342783A Pending AU2021342783A1 (en) 2020-09-17 2021-09-15 Compounds and compositions as sppl2a inhibitors

Country Status (30)

Country Link
US (1) US20230365571A1 (https=)
EP (2) EP4578451A3 (https=)
JP (2) JP7771172B2 (https=)
KR (1) KR20230069947A (https=)
AU (1) AU2021342783A1 (https=)
CA (1) CA3192763A1 (https=)
CL (2) CL2023000728A1 (https=)
CO (1) CO2023004646A2 (https=)
CR (1) CR20230142A (https=)
DK (1) DK4214210T3 (https=)
DO (1) DOP2023000055A (https=)
EC (1) ECSP23027092A (https=)
ES (1) ES3028668T3 (https=)
FI (1) FI4214210T3 (https=)
GE (2) GEAP202516217A (https=)
HR (1) HRP20250562T1 (https=)
HU (1) HUE071569T2 (https=)
IL (1) IL300953B1 (https=)
JO (1) JOP20230044A1 (https=)
LT (1) LT4214210T (https=)
MA (1) MA61557B1 (https=)
MD (1) MD4214210T2 (https=)
MX (1) MX2023003122A (https=)
PE (1) PE20231099A1 (https=)
PL (1) PL4214210T3 (https=)
PT (1) PT4214210T (https=)
RS (1) RS66874B1 (https=)
SI (1) SI4214210T1 (https=)
SM (1) SMT202500216T1 (https=)
WO (1) WO2022058902A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947813A (zh) * 2023-07-06 2023-10-27 绍兴贝斯美化工股份有限公司 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法
US20250263416A1 (en) 2024-02-15 2025-08-21 Incyte Corporation SPPL2a INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
GB9612622D0 (en) 1996-06-17 1996-08-21 Zeneca Ltd Chemical process
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5

Also Published As

Publication number Publication date
DOP2023000055A (es) 2023-06-15
CO2023004646A2 (es) 2023-07-21
SI4214210T1 (sl) 2025-07-31
JP2023541475A (ja) 2023-10-02
MD4214210T2 (ro) 2025-10-31
HUE071569T2 (hu) 2025-09-28
EP4578451A3 (en) 2025-09-17
AU2021342783A9 (en) 2024-09-12
EP4578451A2 (en) 2025-07-02
KR20230069947A (ko) 2023-05-19
MX2023003122A (es) 2023-03-22
CN116615425A (zh) 2023-08-18
PT4214210T (pt) 2025-05-22
IL300953A (en) 2023-04-01
WO2022058902A1 (en) 2022-03-24
IL300953B1 (en) 2026-04-01
PL4214210T3 (pl) 2025-08-18
ECSP23027092A (es) 2023-06-30
JP2026041723A (ja) 2026-03-10
JOP20230044A1 (ar) 2023-02-27
CL2023000728A1 (es) 2023-12-15
CR20230142A (es) 2023-08-25
CA3192763A1 (en) 2022-03-24
EP4214210B1 (en) 2025-04-09
MA61557B1 (fr) 2025-05-30
SMT202500216T1 (it) 2025-07-22
HRP20250562T1 (hr) 2025-07-04
ES3028668T3 (en) 2025-06-19
GEAP202516217A (en) 2025-02-10
LT4214210T (lt) 2025-07-25
GEP20257771B (en) 2025-06-10
DK4214210T3 (da) 2025-06-10
RS66874B1 (sr) 2025-06-30
EP4214210A1 (en) 2023-07-26
JP7771172B2 (ja) 2025-11-17
PE20231099A1 (es) 2023-07-18
US20230365571A1 (en) 2023-11-16
CL2024001312A1 (es) 2024-10-11
FI4214210T3 (fi) 2025-05-26

Similar Documents

Publication Publication Date Title
CN105940002B (zh) ROR-γ的二氢吡咯并吡啶抑制剂
KR20210086674A (ko) Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
JP2026041723A (ja) Sppl2a阻害剤としての化合物及び組成物
CN111164069A (zh) 作为atf4抑制剂用于治疗癌症和其它疾病的n-(3-(2-(4-氯苯氧基)乙酰胺基)双环[1.1.1]戊-1-基)-2-环丁烷-1-甲酰胺衍生物以及相关化合物
KR20150128891A (ko) 인돌아민 2,3-디옥시게나제 (ido)의 억제제
TW201706274A (zh) 吡咯[2,3-d]嘧啶基、吡咯[2,3-b]吡基和吡咯[2,3-b]吡啶基丙烯醯胺及其環氧化物
CN107074805A (zh) 用于治疗疾病的gls1抑制剂
CA2980161A1 (en) Heterocyclic compounds useful as inhibitors of tnf
JP2021528405A (ja) RORγtのモジュレータとしてのアミド置換チアゾール
WO2021117759A1 (ja) 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤
CN116615425B (zh) 作为Sppl2a抑制剂的化合物和组合物
HK40128790A (en) Compounds and compositions as sppl2a inhibitors
EA031310B1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
US20250263416A1 (en) SPPL2a INHIBITORS
EP3759085B1 (en) Substituted cyclohexyl compounds as nop inhibitors
EA048012B1 (ru) Соединения и композиции в качестве ингибиторов sppl2a
US7816378B2 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
WO2025133915A1 (en) Compounds which bind to pnpla3i148m and their use to treat liver diseases
US20220331304A1 (en) Compounds for use in treating neurological disorders
JP2025541737A (ja) Masp-2阻害物質としての縮合ピリミジン
HK40130359A (zh) 犬janus激酶抑制剂及其用途
HK40070643A (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
HK40034295B (en) Substituted cyclohexyl compounds as nop inhibitors
HK40034295A (en) Substituted cyclohexyl compounds as nop inhibitors
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases

Legal Events

Date Code Title Description
SREP Specification republished